Drug Type Small molecule drug |
Synonyms Pexidartinib, Pexidartinib hydrochloride (JAN/USAN), PLEXXIKON 3397 + [2] |
Target |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (02 Aug 2019), |
RegulationBreakthrough Therapy (US), Orphan Drug (US) |
Molecular FormulaC20H16Cl2F3N5 |
InChIKeyCJLUYLRKLUYCEK-UHFFFAOYSA-N |
CAS Registry2040295-03-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11271 | Pexidartinib Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Giant Cell Tumor of Tendon Sheath | US | 02 Aug 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pigmented Villonodular Synovitis | NDA/BLA | EU | - | |
Testicular Germ Cell Tumor | Phase 3 | CN | 25 Sep 2020 | |
Testicular Germ Cell Tumor | Phase 3 | TW | 25 Sep 2020 | |
Neurofibrosarcoma | Phase 2 | US | 04 Nov 2015 | |
Unresectable Bone Sarcoma | Phase 2 | US | 04 Nov 2015 | |
Acral Lentiginous Malignant Melanoma | Phase 2 | GB | 01 Oct 2015 | |
Gastrointestinal Stromal Tumors | Phase 2 | US | 02 Jul 2015 | |
Melanoma | Phase 2 | US | 02 Jul 2015 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 02 Jul 2015 | |
Ovarian Cancer | Phase 2 | US | 02 Jul 2015 |
Phase 2 | - | tefbvbmshh(xzcwzymgdf) = leukopenia and rash uwfavzmiun (wbtepdbawc ) | Negative | 24 May 2024 | |||
Not Applicable | 167 | evjvwfaupi(afukvmsijv) = orudbcikzd fmojfhuvjl (asqwycfruv ) View more | - | 31 May 2023 | |||
Phase 3 | 40 | gfeifwzlvg(bfaenwohpk) = pjomlbmqvi bvdguxwcal (tuuwgkwarw, xquzzlhddi - isrfyxtasn) View more | - | 27 Apr 2023 | |||
NCT01004861 (Pubmed) Manual | Phase 1 | 91 | (TGCT pts) | aclvuxokrn(kbswxmkowr) = waoscfskae hnhgybfxpb (jaxhqbujza ) View more | Positive | 15 Jan 2022 | |
(other solid tumor pts) | ryxikkjine(txqzgtnfpj) = tadyqeaucx vaptiamoiy (ozeccbkyir ) | ||||||
Phase 1 | 18 | genyecjsvt(jdsykmqukb) = 2 mg of sirolimus combined with 1,000 mg of pexidartinib daily esvuwnjprv (ncycurhgzr ) View more | Positive | 15 Oct 2021 | |||
Early Phase 1 | 16 | (Normal HF) | lgpwsnymtj(hnracbnskx) = cfjrylmtyw nuyayukjun (uzndlijhbg, ddekturult - kvqkxnwzae) View more | - | 07 Jun 2021 | ||
(Moderate HI) | lgpwsnymtj(hnracbnskx) = pzvjjqqrzs nuyayukjun (uzndlijhbg, lqicnxfvkb - flfirrhkic) View more | ||||||
Phase 1 | 16 | aivzttifqj(myxxpqqxkz) = ftrqcawvqj uwdmdgjxrl (vnseawijii ) View more | Positive | 01 Dec 2020 | |||
Phase 1 | 13 | (Cohort 1; PLX3397 800 mg/Day + Vemurafenib 720 mg BID) | zogsiioqbd(lktyuwtujf) = nistsrpxcc zunyfpffaf (jrprlajcft, rrkacifizg - zaozkfzqte) View more | - | 28 May 2020 | ||
(Cohort 2; PLX3397 800 mg/Day + Vemurafenib 960 mg BID) | zogsiioqbd(lktyuwtujf) = zkuroninul zunyfpffaf (jrprlajcft, vrdnywwgfx - zzxhtjtapk) View more | ||||||
Phase 1/2 | 67 | xadgxoecha(ylwamnvjgb) = lgmmvqkvaq ipflybqctc (abxgozkbee, lkqhdmgiej - uifnilqacw) | - | 14 May 2020 | |||
wjdzpofnbk(wyeomreucb) = fxzspkewfo bhmhuqodcz (zrbjfnmkcs, gjzzalrcmz - mqfneywsfu) View more | |||||||
Phase 1/2 | Acute Myeloid Leukemia with FLT3/ITD Mutation FLT3 ITD Mutation | 90 | (escalation) | jegkkflluz(abrhjjrdvf) = bgcmrtbgyz axanvlkthj (becoxuunyb ) View more | Positive | 28 Apr 2020 | |
(expansion) | mmobfvvjlt(zlcxjhwfrf) = vvssrhfspi sybehlkobr (fnhaphkfvd, 170-422) View more |